Finding your next opportunity shouldn’t require piecing together multiple databases, alerts and research tools.
Fundz combines its own funding and M&A intelligence with hiring, leadership and other business signals into one connected view of each company, ranks opportunities against your ideal customer profile, and delivers the evidence and verified contacts to act on. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
Apimeds Pharmaceuticals US, Inc.
A senior executive or director joined, left, or changed roles. An 8-K is the notice a US public company must file within four business days of a major event.
www.apimedsus.comAI Executive Summary
AI-powered analysis of 8-K filing content
Apimeds Pharmaceuticals appointed Eric Sherb as Chief Financial Officer effective October 1, 2026, following the resignation of interim CFO Erick Frim. This leadership transition occurs during a critical innovation period for the pharmaceutical company.
Key Takeaways
Erick Frim resigned as Interim CFO on September 29, 2026, effective immediately, with no disagreements cited regarding company operations or policies
Eric Sherb was appointed as the new Chief Financial Officer by the Board of Directors on September 30, 2026, with an effective date of October 1, 2026
2 more takeaways
Related Filings (1)
1 more filing from Apimeds Pharmaceuticals US, Inc. in the last 90 days
Filing Overview
What This Means
Apimeds Pharmaceuticals US, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.